Nurse warns of six little-known signs of 'silent' kidney cancer surging in under-50s
Health •
Kidney Cancer UK nurse urges patients to 'trust your instincts' as cases rise among younger adults and many tumours are found incidentally
Health News
Alcohol linked to widespread organ damage but health begins to recover almost immediately, experts say
Health •
World Health Organization classifies alcohol as a Group 1 carcinogen; clinicians say stopping or cutting back yields measurable benefits within days to months
Eli Lilly’s once‑daily oral weight‑loss pill could reach UK as early as 2026, trials show 12.4% average weight loss
Health •
Orforglipron, an oral GLP‑1 therapy, delivered significant weight reductions in late‑stage testing but produced gastrointestinal side effects; company plans regulatory filings by year‑end
Eli Lilly seeks approval for once‑daily oral weight‑loss pill after positive trial results
Health •
Orforglipron, an oral GLP‑1 receptor therapy, cut weight by an average 12.4% in a late‑stage trial and could be submitted for regulatory review by year‑end
Eli Lilly says once‑daily oral weight‑loss pill could reach UK as soon as 2026
Health •
Orforglipron cut weight by an average 12.4% in a 3,127‑participant trial; company plans regulatory submissions by year‑end
Eli Lilly says once‑daily obesity pill could reach UK next year after trials show 12.4% weight loss
Health •
Orforglipron, an oral GLP‑1 therapy, reduced weight by an average of 12.4% in a 72‑week trial; company plans regulatory submissions and cites similar side‑effect profile to injectable treatments
Eli Lilly’s oral GLP-1 pill could reach UK as soon as next year, trials show average 12.4% weight loss
Health •
Company plans regulatory submissions after late-stage trial results; pill aims to offer a room-temperature, once-daily alternative to injectable obesity drugs
Eli Lilly says once‑a‑day oral GLP‑1 pill could reach UK next year after late‑stage trial shows 12% weight loss
Health •
Orforglipron, an oral drug that targets GLP‑1 receptors, produced an average 12.4% weight reduction in a 3,127‑participant study; company plans regulatory filings by year‑end
Eli Lilly says oral GLP‑1 pill orforglipron could be available next year after 72‑week trial
Health •
Company plans regulatory filings after phase‑3 results showing average 12.4% weight loss; pill aimed at patients who prefer not to use injectable therapies